Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

h the use of nucleoside analogues alone or in combination with other antiretrovirals. Viread is not approved for the treatment of chronic hepatitis B and the safety and efficacy of Viread have not been established in patients coinfected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Viread. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are co-infected with HIV and HBV and discontinue Viread. If appropriate, initiation of anti-hepatitis B therapy may be warranted.

Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported in association with the use of Viread. It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy with Viread and as clinically appropriate during therapy. Coadministration of Viread and didanosine should be undertaken with caution. Patients should be monitored closely for didanosine-associated adverse events, and didanosine should be discontinued if these occur. Patients on atazanavir and lopinavir/ritonavir plus Viread should be monitored for Viread-associated adverse events, and Viread should be discontinued if these occur. When co-administered with Viread, it is recommended that atazanavir 300 mg be given with ritonavir 100 mg. Atazanavir without ritonavir should not be co-administered with Viread.

Decreases in bone mineral density (BMD) at the lumbar spine and hip have been seen with the use of Viread. The effects of Viread-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown. Changes in body fat have been observed in patients taking anti-HIV medicines. The cause and long-term health effect of these changes are unknown. Immune Reconstitution Syndrome has been reported in patients treated with combination therapy, including Viread.

The m
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:7/31/2015)... July 31, 2015  Semler Scientific, Inc. (Nasdaq: ... services to healthcare insurers and physician groups, today reported ... 2015. "In the second quarter of ... revenue growth of 54%, quarter over quarter revenue growth ... installed base of FloChec® units of 18%," said Doug ...
(Date:7/31/2015)... , July 31, 2015 According ... Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry ... Weighing) - Global Analysis & Forecast to 2019", published ... pegged at $911.1 Million 2014 and is estimated to ... CAGR of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... 2015 Mettler-Toledo International Inc. (NYSE: MTD ... below are the highlights: , Sales in ... the prior year. Reported sales decreased 4% as currency ... , Net earnings per diluted share as reported (EPS) ... Adjusted EPS was $2.80 , an increase of ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
... , Company expects to meet or exceed 2011 EPS ... declines due to Zyprexa patent expiration. , 2012 revenue ... Company expects to keep 2012 operating expenses essentially flat versus 2011. ... the range of $3.10 - $3.20. , R&D pipeline ...
... January 5, 2012 Predator Nutrition, one of ... burners and creatine , raised £762 and invaluable ... football tournament in Leeds in December. The sports ... made up of business partners and close friends and family ...
Cached Medicine Technology:Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 2Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 3Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 4Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 5Predator Nutrition Tackles Africa in Charity Football Tournament 2
(Date:8/1/2015)... ... 01, 2015 , ... The condition where veins are enlarged and gnarled is ... pain and discomfort. Those who spend a lot of time on their feet and ... is doing what it can to create awareness and provide a cure in observance ...
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, Symantec released a security ... have been behind the attack on Anthem Inc. which resulted in one of the ... hole attacks and spear phishing campaigns. , For Joe Caruso, founder and ...
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, ... are the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) ... well as tried-and-true products that have stood the test of time. These include ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest applicator ... new applicator in the United States as an upgrade to the CoolSmooth applicator cleared ... applicator required a 2 hour treatment time. The new CoolSmooth Pro reduces the ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... health will be presented in Denver April 30-May 3, as ... (PAS). This year,s gathering is a joint meeting with the ... leaders in academic pediatrics from around the world are expected ... Journalists will have access to hundreds of scientists who ...
... a tight spot, the cell cycle regulator p21 halts ... damage, or if all else fails, to initiate programmed ... dispense with the regular transcriptional entourage, p21Cip1 still requires ... the editing of transcripts, to be expressed, found researchers ...
... FRIDAY, April 1 (HealthDay News) -- More than one-quarter of ... have had children with different men, a new study shows. ... nearly 4,000 women who were past their child-bearing years and ... as part of the National Longitudinal Survey of Youth. ...
... bag: PUMA contributes to ulcerative colitis Ulcerative ... be related to aberrant activation of the immune system ... regulated cell death (apoptosis) of the intestinal epithelial cells ... molecular mechanisms that control the cellular response to inflammation ...
... get their information about vaccines from their children,s doctors, ... friends and family members and even celebrities as sources ... a national survey conducted by University of Michigan researchers ... information in regards to vaccines, as well as to ...
... too late in children and adolescents. In the current ... Int 2011; 108: 173-79), Susanne Walitza and her colleagues ... positively affect the course of the disease. Compulsive ... adolescents, is present in up to 87% of all ...
Cached Medicine News:Health News:Children's health is focus of annual meeting of Pediatric Academic Societies 2Health News:'SKIP'-ing splicing forces tumor cells to undergo programmed cell death 2Health News:'SKIP'-ing splicing forces tumor cells to undergo programmed cell death 3Health News:Many Moms Have Kids With Different Dads, U.S. Study Finds 2Health News:JCI online early table of contents: April 1, 2011 2Health News:JCI online early table of contents: April 1, 2011 3Health News:JCI online early table of contents: April 1, 2011 4Health News:JCI online early table of contents: April 1, 2011 5Health News:JCI online early table of contents: April 1, 2011 6Health News:JCI online early table of contents: April 1, 2011 7Health News:JCI online early table of contents: April 1, 2011 8Health News:JCI online early table of contents: April 1, 2011 9Health News:JCI online early table of contents: April 1, 2011 10Health News:JCI online early table of contents: April 1, 2011 11Health News:U-M experts: Parents trust doctors most when it comes to information about vaccine safety 2
... OptiEdge offers design innovations that ensure outstanding ... handling. The biostable acrylic material of the ... the patented OptiEdge is designed to both ... of contact with the posterior capsule; and ...
... posterior chamber lenses are optical implants for ... in the visual correction of aphakia in ... The optical portion consists of a high ... have biconvex optics and supporting haptics of ...
... Alcon introduces an intraocular lens ... Similar to the natural human lens, ... both UV and high-energy blue light. ... it won't spoil your patient's view. ...
... USIOL lenses are manufactured using ... processes. Perspex CQ UV PMMA ... multi-piece and single piece lenses. ... in both nonphaco and phaco ...
Medicine Products: